Hologic

Kate Madden Yee

Oct 22, 2007

(Booth 7113) Hologic of Bedford, MA, will demonstrate its Fluoroscan InSight mini C-arm at RSNA 2007.

The device is designed to deliver high-resolution, low-dose images for extremity surgery to hospital operating room and emergency room departments, as well as outpatient surgery centers and doctors' offices.

Road to RSNA 2024: Molecular Imaging Preview

November 21, 2024

FAPI-PET/CT superior to FDG-PET/CT in liver cancer patients

November 21, 2024

FAPI-PET/CT improves detection of primary and metastatic breast cancer

November 21, 2024

Theranostics cost-effective in men with mCRPC

November 21, 2024

Road to RSNA 2024: Molecular Imaging Preview

Theranostics could be cited for speeding in this year’s Road to RSNA. It's only been a few years since a dedicated track in nuclear medicine and molecular imaging was established at the meeting, and the practice already dominates it.

November 21, 2024

FAPI-PET/CT superior to FDG-PET/CT in liver cancer patients

Ga-68 FAPI-PET/CT imaging appears superior to FDG-PET/CT for assessing hepatocellular carcinomas. In a large prospective trial, the approach was more accurate – enough so that it could possibly replace FDG-PET/CT in the future.

November 21, 2024

FAPI-PET/CT improves detection of primary and metastatic breast cancer

Ga-68 FAPI-PET/CT significantly enhances the detection rate and staging of primary and metastatic breast cancer, demonstrating superior sensitivity and specificity compared with F-18 FDG-PET/CT.

November 21, 2024

Theranostics cost-effective in men with mCRPC

Using theranostic radionuclides such as Ra-223 or Lu-177 to treat men with metastatic castration-resistant prostate cancer (mCRPC) is more cost-effective in the long term than traditional chemotherapy and radiotherapy, suggests a study in this session.

November 21, 2024

Treatment-related factors enhance PSMA expression

Certain prostate cancer features on PSMA-PET may be useful in selecting candidates who are more likely to respond to Lu-177 PSMA-617, according to a presentation in this session.

November 21, 2024

F-18 PSMA-DCFPyL and Ga-68 PSMA-11 deemed equivalent

PET radiopharmaceuticals F-18 PSMA-DCFPyL and a Ga-68 PSMA-11 appear equivalent for determining patient eligibility for prostate cancer treatment with Lu-177 PSMA-617, researchers say.

November 21, 2024

AI segments lesions on Ga-68 DOTATATE PET/CT images

In this session, researchers will present an automated deep-learning AI model that could help clinicians segment rare neuroendocrine tumors on whole-body 3D gallium-68 (Ga-68) DOTATATE PET/CT images.

November 21, 2024

Are Lu-177 PSMA-617 outcomes applicable in a community setting?

During this session on theranostics, a study suggests that targeted education is needed to support the delivery of Lu-177 PSMA-617 to patients.

November 21, 2024

FES-PET shows promise for staging invasive lobular carcinoma

A mid-study analysis presented during this session suggests that F-18 fluoroestradiol (FES) PET/CT may detect unsuspected stage IV invasive lobular carcinoma.

November 21, 2024

Dedicated brain PET system shows promise in Alzheimer’s disease imaging

A high-resolution dedicated brain PET system could augment visual reading in the early diagnosis of dementia, suggests a study in this session.

November 21, 2024

Can AI chatbots answer questions for patients on Lu-177 PSMA-617 therapy?

In response to common questions from Lu-177 PSMA-617 patients, Gemini provided easy-to-understand answers and ChatGPT-4 demonstrated high accuracy, yet neither AI chatbot provided completely accurate answers to all questions.

November 21, 2024

AI denoising software valuable for amyloid PET/CT studies

A study in this session suggests that count-poor and noisy amyloid brain PET/CT studies can be rendered clinically useful through AI denoising software.

November 21, 2024

Page 1 of 554